JamesAShaymanMD

Physician

Dr. Shayman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1500 East Medical Center Dr
University Hospital - Im Nephrology Inpatient
Ann Arbor, MI 48109
Phone+1 734-888-2871

Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1985 - 1985
Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1983 - 1984
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1980 - 1983
Washington University in St. Louis School of MedicineClass of 1980

PubMed

1 citations
The role of lysosomal phospholipase A2 in the catabolism of bis(monoacylglycerol)phosphate and association with phospholipidosis.
Akira Abe, Vania Hinkovska-Galcheva, Philip Bouchev, Renee Bouley, James A Shayman
Journal of Lipid Research. 2024-07-01
3 citations
Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1.
Jonathan M Shillingford, James A Shayman
American Journal of Physiology. Renal Physiology. 2023-04-01
Moving the Needle: Accelerating Drug Discovery in Nephrology.
James A Shayman
Journal of the American Society of Nephrology. 2023-03-01

Lectures

Entrepreneurship and Innovation in Kidney Care
American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/8/2019

Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts SayFebruary 5th, 2021
Sanofi Pivotal Trial to Target Driver of Cyst Growth in PKDNovember 12th, 2018
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis from the HALT-PKD TrialsJanuary 4th, 2018

Lysosomal Phospholipase A2 In Autoimmune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2012
The Pharmacological Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2012
The Pharmacologic Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2008
Glycosphingolipids In Diabetes MellitusNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1999
Glycosphingolipid And Renal CarcinomaNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
Sphingolipids And Polycystic Kidney DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1997
Renal Polyol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1994
Peptide Hormone Stimulated Inositol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1989
Peptide Hormone Stimulated Inositol MetabolismNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985